Han Biomedical

Han Biomedical EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Han Biomedical (6999.TWO) as of Oct 26, 2026 is 10.15 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 11.08 % — a change of -8.38% (lower).

EBIT/Assets

10.15 %

YoY

-8.38%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Han Biomedical is 2024 10.15 % . Operating Income to Assets Ratio (EBIT/Assets) of Han Biomedical was 2023 11.08 % . It decreases by -8.38% lower compared to the previous year.

The Han Biomedical EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2022
11.21 TWD
Jan 1, 2023
11.08 TWD
Jan 1, 2024
10.15 TWD
The Han Biomedical EBIT/Assets history
YEAREBIT/AssetsYoY
10.15 %-8.38%
11.08 %-1.11%
11.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Han Biomedical stock

Operating Income to Assets Ratio (EBIT/Assets) of Han Biomedical is 10.15 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of Han Biomedical changed from 11.08 % to 10.15 %, representing a -8.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Han Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Han Biomedical

All Key Metrics — Han Biomedical